A Phase II Study of Nimotuzumab in Patients with Unresectable Stage III Non-small Cell Lung Cancer
Phase 2
- Conditions
- nresectable stage III non-small cell lung cancer
- Registration Number
- JPRN-jRCT2080220796
- Lead Sponsor
- DAIICHISANKYO Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
Patients with unresectable stage IIIA or IIIB of NSCLC
Patients who are judged to be suitable for radical radiotherapy
Exclusion Criteria
Patients with another active malignancy
Patients who have obvious pulmonary fibrosis or interstitial pneumonia by chest CT-scans
Patients with severe or uncontrolled complications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tolerability<br>The proportion of patients who have completed all of the protocol-stipulated treatments
- Secondary Outcome Measures
Name Time Method Safety, response rate, progression-free survival , progression-free survival rate, and survival rate<br>NCI-CTC (ver.3.0), RECIST (ver. 1.1)